Emerging Trends to Drive Influenza Drug Market Growth at 6% CAGR Through 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Influenza Drug Market Size Growth Forecast: What to Expect by 2025?
The size of the influenza drug market has seen substantial growth in the past few years. The market-which was valued at $0.98 billion in 2024-is expected to increase to $1.04 billion in 2025, indicating a compound annual growth rate (CAGR) of 6.4%. The growth experienced during the historic period can be attributed to factors such as the surge in seasonal influenza outbreaks, expansion in healthcare spending, rising awareness about vaccination, broader use of antiviral drugs, and the growth of government-backed immunization programs.

How Will the Influenza Drug Market Size Evolve and Grow by 2029?
In the coming years, the influenza drug market is projected to experience significant growth, with a 6.0% compound annual growth rate (CAGR) leading to an estimated valuation of $1.32 billion in 2029. This forecasted growth is due to several factors, including the increased incidents of flu-like diseases, improvements in global healthcare accessibility, advancements in healthcare facilities in developing economies, growing demand for combined treatment therapies, and an increased emphasis on preventive health care. Key trends for the forecast period encompass innovation in the creation of vaccines, advancements in diagnostics, the development of next-generation antivirals, progress in antiviral research, and improvements in drug delivery systems.

View the full report here:
https://www.thebusinessresearchcompany.com/report/influenza-drug-global-market-report

What Drivers Are Propelling the Growth of Influenza Drug Market Forward?
The escalation in the number of influenza infections is anticipated to fuel the expansion of the influenza drug market. These infections are contagious respiratory illnesses stemming from influenza viruses, leading to symptoms like fever, cough, sore throat, and body aches. This surge in influenza infections is attributed to frequent viral mutations that lessen the effectiveness of vaccines and heighten vulnerability to outbreaks in the population. Influenza drugs thwart this rise by offering effective treatment options that alleviate the severity of the disease and help manage its widespread transmission. For example, in September 2023, the US Centers for Disease Control and Prevention (CDC) predicted that 31 million symptomatic illnesses, 14 million medical visits, 360,000 hospitalizations, and 21,000 deaths were caused by influenza virus infections during the 2022-2023 season. Therefore, the escalating numbers of influenza infections are driving the influenza drug market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27317&type=smp

Which Emerging Trends Are Transforming the Influenza Drug Market in 2025?
In an effort to improve the effectiveness of treatments, patient compliance, and overall therapeutic results, primary enterprises participating in the influenza drug market are directing their focus towards advancements in technology, one such area is drug formulation. Drug formulation typically involves the unification of excipients and inert materials with active pharmaceutical ingredients (APIs). This process results in the creation of effective drug products possessing desired characteristics. A case in point occurred in August 2024 when F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical and diagnostic focused company, unveiled their Baloxavir Marboxil for Suspension. It's a strawberry-flavored, single-dose oral antiviral intended for children, aiding parents in delivering accurate weight-based dosing, therefore enhancing both the administration process and compliance. This innovation offers a precise, home-based medication delivery option that fits the prescription delivery service context. It enables caregivers to handle pediatric influenza treatment conveniently at home following a prescription. While it features benefits such as a novel mechanism specificity and better adherence, there is potential for resistance to develop over time, particularly in pediatric patients.

What Are the Key Segments in the Influenza Drug Market?
The influenza drug market covered in this report is segmented

1) By Type: Influenza A, Influenza B, Influenza C
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Route Of Administration: Oral, Intranasal, Intravenous, Intramuscular, Subcutaneous
4) By Mechanism Of Action: Neuraminidase Inhibitors, Cap-Dependent Endonuclease Inhibitors, Fusion Inhibitors, M2 Ion Channel Inhibitors, Host Cell Protease Inhibitors, Immunomodulatory Agents, Ribonucleic Acid (RNA) Polymerase Inhibitors, Hemagglutinin Stem Binders, Cytokine Inhibitors, Host Factor Targeting
5) By End-User: Hospitals And Clinics, Pharmacies, Vaccination Centers, Research Institutions, Government Health Agencies, Long-Term Care Facilities, Community Health Centers, Corporate Health Programs

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=27317&type=smp

Who Are the Key Players Shaping the Influenza Drug Market's Competitive Landscape?
Major companies operating in the influenza drug market are F. Hoffmann-La Roche Ltd., Pfizer Inc., AstraZeneca PLC, GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Moderna Inc., BioNTech SE, Shionogi & Co. Ltd., Green Cross Corp, Emergent BioSolutions Inc., Novavax Inc., Hualan Biological Engineering Inc., Serum Institute of India Pvt. Ltd., CSL Seqirus Pty Ltd., BioCryst Pharmaceuticals, Inc., SAB Biotherapeutics Inc., Viriom Inc., Osivax SAS, Cocrystal Pharma Inc., Sinovac Biotech Ltd.

What Geographic Markets Are Powering Growth in the Influenza Drug Market?
North America was the largest region in the influenza drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=27317

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.